Feng Du
Impact in
- Oncology top 2%
- Lung Cancer Research Studies
- Peptidase Inhibition and Analysis
- Cancer Research top 5%
- Cancer-related molecular mechanisms research
Papers in
- Oncology 47
- HER2/EGFR in Cancer Research 14
- Cancer Treatment and Pharmacology 12
- Colorectal Cancer Surgical Treatments 7
-
- Gastric Cancer Management and Outcomes 15
- Co-authors
- Jiuda Zhao (18 shared papers)Fangchao Zheng (19 shared papers)Guoshuang Shen (11 shared papers)Dengfeng Ren (7 shared papers)Fuxing Zhao (6 shared papers)Raees Ahmad (5 shared papers)Yongkun Sun (7 shared papers)Jinwan Wang (6 shared papers)
- Journals
- Oncotarget (5 papers)BMC Cancer (3 papers)Frontiers in Oncology (3 papers)Journal of Clinical Oncology (3 papers)Breast Cancer Research and Treatment (3 papers)
- Partner nations
- ChinaUnited StatesEthiopia
In The Last Decade
Feng Du
73 papers receiving 2.2k citations
Feng Du's Hit Papers
Peers
Comparison fields: 5 of 107
- Oncology 1.3k
- Cancer Research 503
- Pulmonary and Respiratory Medicine 883
- Pathology and Forensic Medicine 204
- Surgery 470
Countries citing papers authored by Feng Du
This map shows the geographic impact of Feng Du's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Feng Du with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Feng Du more than expected).
Fields of papers citing papers by Feng Du
This network shows the impact of papers produced by Feng Du. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Feng Du. The network helps show where Feng Du may publish in the future.
Co-authors
The 25 scholars most cited alongside Feng Du, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 75 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development Hit paper breakdown → | 2018 | 446 |
| 2 | Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors Hit paper breakdown → | 2016 | 332 |
| 3 | 2018 | 245 | |
| 4 | 2017 | 112 | |
| 5 | 2018 | 91 | |
| 6 | 2018 | 78 | |
| 7 | 2015 | 60 | |
| 8 | 2020 | 55 | |
| 9 | 2015 | 47 | |
| 10 | 2017 | 41 | |
| 11 | 2015 | 38 | |
| 12 | 2017 | 37 | |
| 13 | 2016 | 37 | |
| 14 | 2019 | 32 | |
| 15 | 2013 | 32 | |
| 16 | 2019 | 31 | |
| 17 | 2020 | 30 | |
| 18 | 2021 | 30 | |
| 19 | 2021 | 29 | |
| 20 | 2014 | 24 |
About Feng Du
Feng Du is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Surgery and Molecular Biology, having authored 75 papers that have together received 2.2k indexed citations. Recurring topics across this work include Gastric Cancer Management and Outcomes (15 papers), HER2/EGFR in Cancer Research (14 papers), Breast Cancer Treatment Studies (14 papers), Cancer Treatment and Pharmacology (12 papers), RNA modifications and cancer (11 papers), Esophageal Cancer Research and Treatment (8 papers), Colorectal Cancer Surgical Treatments (7 papers) and Colorectal and Anal Carcinomas (7 papers). The work is most often cited by research in Oncology (1.3k citations), Cancer Research (503 citations), Pulmonary and Respiratory Medicine (883 citations), Pathology and Forensic Medicine (204 citations) and Surgery (470 citations). Feng Du has collaborated with scholars based in China, United States and Ethiopia. Frequent co-authors include Jiuda Zhao, Fangchao Zheng, Guoshuang Shen, Dengfeng Ren, Fuxing Zhao, Raees Ahmad, Yongkun Sun, Jinwan Wang, Yihebali Chi and Ziyi Wang. Their work appears in journals such as Oncotarget, BMC Cancer, Frontiers in Oncology, Journal of Clinical Oncology and Breast Cancer Research and Treatment.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.